| Symbol | MEDIF |
|---|---|
| Name | MEDIPHARM LABS CORPORATION |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | L4N 2L1 Canada ON 151 John Street |
| Telephone | +1 705-719-7425 |
| Fax | — |
| — | |
| Website | http://www.medipharmlabs.com |
| Incorporation | CA |
| Incorporated On | 2017 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | MNP LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Toronto Stock Exchange |
| CIK | — |
| Description | Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing Licence for the extraction of natural cannabinoids. MediPharm carries out its operations in compliance with all applicable laws in the countries in which it operates. Additional info from OTC: |
No news found.